Home
Live Updates
Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024 : comparemela.com
Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024
CAMBRIDGE, Mass., April 24, 2024 -- Cullinan Therapeutics, Inc. , a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced that clinical data from its Phase 1...
Related Keywords
Chad ,
Cambridge ,
Cambridgeshire ,
United Kingdom ,
Chicago ,
Illinois ,
United States ,
American ,
Jeffrey Jones ,
Rose Weldon ,
Ignacio Melero ,
American Society Of Clinical Oncology ,
Cullinan Therapeutics Inc ,
Linkedin ,
Exchange Commission ,
Nasdaq ,
Clinical Oncology ,
Annual Meeting ,
Chief Medical Officer ,
Developmental Therapeutics ,
Private Securities Litigation Reform Act ,
Annual Report ,
Markets ,
comparemela.com © 2020. All Rights Reserved.